Nachrichten zur Moderna Aktie

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Moderna, Inc. - MRNA

NEW YORK, July 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

GSK Secures mRNA Vaccines For Bird Flu, COVID And Seasonal Flu From Struggling Biotech CureVac

mRNA specialist CureVac, which struggled to compete with the likes of Pfizer, Moderna and BioNTech, said it will focus on…

Moderna (MRNA) Secures BARDA Funding for Bird Flu Vaccine

Moderna (MRNA) expects this funding to help support the development of its mRNA-based pre-pandemic vaccine against the H5 influenza virus,…

U.S. awards Moderna $176 million to produce bird flu vaccine

The U.S. government has awarded $176 million to Moderna to advance development of its bird flu vaccine, the company said…

Moderna Scores Federal Funding For mRNA Bird Flu Vaccine As Pandemic Fears Grow

Funding from U.S. biodefense agency Barda will support Moderna in developing an mRNA-based pandemic flu vaccine as fears grow the…

CHMP Endorses Modernas (MRNA) mRNA-based RSV Vaccine

If approved, the RSV vaccine will be Modernas (MRNA) second approved product in the European Union.…

Moderna: Really Strong Competition

…

Weekly Update: Rück- und Ausblick u.a. Abercrombie, Airbus, Bitcoin, Covestro, Moderna, Nike AG

Christian Hollendieck, Spezialist Aktien der ICF BANK AG, fasst die vergangene Handelswoche zusammen. Der Deutsche Leitindex bewegt sich weiter in…

IRW-News: Moderna Inc.: Ausschuss für Humanarzneimittel der EMA gibt positive Stellungnahme ab und empfiehlt Marktzulassung von Modernas RSV-Impfstoff mRESVIA(R)

IRW-PRESS: Moderna Inc.: Ausschuss für Humanarzneimittel der EMA gibt positive Stellungnahme ab und empfiehlt Marktzulassung von…

IRW-News: Moderna Inc.: Ausschuss für Humanarzneimittel der EMA gibt positive Stellungnahme ab und empfiehlt Marktzulassung von Modernas RSV-Impfstoff mRESVIA(R)

IRW-PRESS: Moderna Inc.: Ausschuss für Humanarzneimittel der EMA gibt positive Stellungnahme ab und empfiehlt Marktzulassung von Modernas RSV-Impfstoff mRESVIA(R)CAMBRIDGE, MA…

Moderna: Erhöhtes Risiko für RSV-Schätzungen - Aktienanalyse

New York (www.aktiencheck.de) - Moderna-Aktienanalyse von Evercore ISI: Cory Kasimov, Analyst von Evercore ISI, bestätigt sein Rating und Kursziel für die…

Moderna: Season 2 RSV-Daten am unteren Ende der Erwartungen - Aktienanalyse

New York (www.aktiencheck.de) - Moderna-Aktienanalyse von Jefferies & Co: Die Analysten von Jefferies & Co raten in einer aktuellen Aktienanalyse weiterhin…

Moderna massiv unter Druck – was ist da los?

Die Aktie von Moderna stand am Mittwoch massiv unter Druck. Mit einem Verlust von mehr als zehn Prozent war sie…

GSK and Moderna slide on RSV vaccine CDC updates

GSK PLC (LSE:GSK, NYSE:GSK) shares fell 6% after US authorities recommended restrictions on doses of any respiratory syncytial virus (RSV) vaccine.…

GSK and Moderna RSV vaccine sell-off is overdone, say analysts

After GSK PLC (LSE:GSK, NYSE:GSK) shares fell sharply on the back of US authorities restricting doses of respiratory syncytial virus (RSV)…

Moderna Aktie stürzt ab - was ist los beim BioNTech-Konkurrenten?

In den letzten Monaten hat sich die Moderna Aktie weit besser entwickelt als der Aktienkurs des Konkurrenten BioNTech. Gestern aber…

Moderna (MRNA) Shares Decline on RSV Vaccine Efficacy Data

Moderna (MRNA) stock sinks after new data shows the efficacy of its mRNA-based RSV vaccine fell sharply in the second…

Moderna shares decline, RSV vaccine efficacy lags behind competitors By Investing.com

Moderna shares decline, RSV vaccine efficacy lags behind competitors…

Moderna RSV Vaccine Efficacy Sinks Over Time, CDC Documents Show

Moderna Inc. shares sank after new data showed the efficacy of its RSV shot fell sharply in the second year…

Moderna says its RSV shot is 50% effective after 18 months

In their clinical trials, GSKs RSV vaccine Arexvy was 78% effective in preventing severe RSV over a second year and…

Oncology Stocks: 8 Biggest NASDAQ Companies in 2024

The wide-ranging oncology market covers every area of cancer care, from diagnosis to treatment.Coming in only after cardiovascular disease, cancer…

Moderna: Kursziel angehoben

Charlotte (www.aktiencheck.de) - Rating-Update: Geoff Meacham, Analyst von BofA Securities, stuft die Aktie von Moderna Inc. (ISIN: US60770K1079, WKN: A2N9D9, Ticker-Symbol:…

Bei Moderna geht es jetzt ans Eingemachte. Seien Sie vorbereitet!

Eine Engelsgeduld brauchen momentan die Anteilseigner von Moderna. So beträgt das Minus im Vergleich zum Vorwochenschluss 2,17 Prozent. Mit Rücksetzern…

Moment Of Truth Approaches For Modernas RSV Vaccine

…

Modernas (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal

Data from a late-stage study shows that Modernas (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared…

Moderna: Gewinne laufen lassen! Aktienanalyse

Kulmbach (www.aktiencheck.de) - Moderna-Aktienanalyse von "Der Aktionär": Marion Schlegel vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie von…

Moderna: RSV-Impfstoff mResvia im Fokus - Kursziel auf 179 USD erhöht - Aktienanalyse

New York (www.aktiencheck.de) - Moderna-Aktienanalyse von Oppenheimer: Hartaj Singh, Analyst von Oppenheimer, stuft die Aktie von Moderna Inc. (ISIN: US60770K1079, WKN:…

I’m relieved AI has come at the end of my investing career

Modern tech plays on our predilection for shortcuts – but it isn’t a quick-fix to getting rich…

Moderna price target raised at Oppenheimer after RSV vaccine approval By Investing.com

Moderna price target raised at Oppenheimer after RSV vaccine approval…

3 actions extraordinary people take to achieve what seems impossible, from the co-founder of Moderna

A mindset of "paranoid optimism" can help you tackle the most improbable challenges, according to Moderna co-founder and chairman Noubar…

Moderna president: Company outlook stabilizing thanks to new flu-COVID vaccine data

…

Moderna (MRNA) COVID-Flu Combo Jab Meets Late-Stage Study Goal

Data from a late-stage study shows that Modernas (MRNA) experimental COVID-19-influenza combination vaccine generates higher immune responses when compared to…

Moderna, Inc. (MRNA) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)

…

Moderna: Neues Kursziel - Aktienanalyse

New York (www.aktiencheck.de) - Moderna-Aktienanalyse von Jefferies & Co: Michael Yee, Analyst von Jefferies & Co, rät in einer aktuellen Aktienanalyse…

Modernas COVID-Flu Vaccine Shows Stronger Immune Response Than Individual Shots, Late-Stage Trial Finds

Moderna said it will talk with regulators to figure out next steps for its combination COVID-flu vaccine and will present…

Modernas combination Covid, flu vaccine is more effective than existing shots in late-stage trial

Moderna is the first company to release positive phase three data on a Covid and flu combination shot, giving it…

Moderna (MRNA) Submits Updated COVID-19 Jab to FDA for Review

Moderna (MRNA) completes regulatory filing of its Spikevax 2024-2025 formula, targeting the COVID-19 variant JN.1 to the FDA for the…

FDA approves GSKs RSV vaccine for high-risk adults ages 50 to 59, expanding shots reach

The FDAs expanded approval could help GSK maintain its dominance in the RSV market, which includes shots from Pfizer and…

Moderna: Erneut gute Nachrichten von der FDA - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Moderna-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Moderna Inc. (ISIN: US60770K1079,…

Moderna, Inc. (MRNA) Jefferies 2024 Global Healthcare Conference (Transcript)

…

CureVac, Moderna und Co: Alarmierender Todesfall – Aktien ziehen an

Die CureVac-Aktie steigt, auch die Moderna-Aktie befindet sich im Aufwind.…

CureVac, Moderna & Co: Aktien ziehen kräftig an – was ist da los?

Die Aktien der Impfstoff-Unternehmen CureVac, Moderna & Co konnten am Mittwoch weitere deutliche Zugewinne verzeichnen. Bei Moderna ging es im…

CureVac, Moderna & Co: Aktien ziehen kräftig an – was ist da los?

Die Aktien der Impfstoff-Unternehmen CureVac, Moderna & Co konnten am Mittwoch weitere deutliche Zugewinne verzeichnen. Bei Moderna ging es im…

DAX: EZB-Zinsentscheid, TUI, Traton, SAP, CureVac, Moderna, Siemens Energy, Bayer, Nvidia im Fokus

Der DAX hat sich am Mittwoch stark präsentiert. Er ging am Ende mit einem Plus von 0,9 Prozent auf 18.575,94…

Updated Covid-19 Vaccine Targeting JN.1 Recommended By FDA Panel

An FDA panel recommended that Moderna, Pfizer-BioNTech, and Novavax should develop new Covid-19 vaccines that target the JN.1 variant of…

FDA Panel Recommends New COVID Vaccines For JN.1 Lineage By Fall

Drug manufactures Moderna, Pfizer and Novavax said they expect the new vaccines will be available this fall in time for…

Moderna, Inc. (MRNA) Moderna Oncology Investor Event (Transcript)

…

What To Know About Personalized mRNA Cancer Vaccines After Promising Trials From Moderna And Merck

Moderna and Merck celebrated promising data on an experimental melanoma skin cancer vaccine this week, one of several trials testing…

Moderna: Kurszielerhöhung

Toronto (www.aktiencheck.de) - Rating-Update: Luca Issi, Analyst vom Investmenthaus RBC Capital Markets, stuft die Aktie von Moderna Inc. (ISIN: US60770K1079, WKN:…

Moderna, Merck shares rise as combined melanoma therapy shows improved survival rate By Investing.com

Moderna, Merck shares rise as combined melanoma therapy shows improved survival rate…